Skip to content

Study · Case report or series · n = 1 · 2025

4 results

Refractory Dysmenorrhea Managed With a Glucagon-Like Peptide-1 Agonist: A Case Report.

Tran M, Swartz N, Elisèe SD

Cureus13 Jan 2025

PMID39944451 (opens in a new tab)PMCIDPMC11821293 (opens in a new tab)DOI10.7759/cureus.77387 (opens in a new tab)PepBankPUB-39944451
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Dysmenorrhea includes symptoms such as abdominal pain, nausea, and vomiting. It is a clinical diagnosis with typical treatment involving the use of non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapy. Even with conventional treatment, many women deal with dysmenorrhea refractory to treatment. They are often subject to dealing with the adverse effects of those treatments, such as peptic ulcer disease. We present a case of a patient with severe refractory dysmenorrhea who was able to minimize symptoms with the use of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist. With no changes in the patient's lifestyle and no additional medications added, the semaglutide therapy was able to minimize the patient's symptoms to where she was able to continue activities of daily living and minimize the use of NSAID therapy. Moreover, the patient experienced no changes in weight and only transient loss of appetite while on semaglutide. We hypothesize that anti-estrogenic and anti-inflammatory properties are potential mechanisms of action in this case. This case brings to light the possible multifaceted applications of GLP-1 agonists beyond weight control and diabetes. The outcome of this case suggests that a controlled trial of GLP-1 agonist therapy is warranted to determine its potential for the management of dysmenorrhea.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one patient with severe refractory dysmenorrhea, semaglutide minimized symptoms so that she could continue daily activities.

    In plain wordsIn one woman with severe period pain that did not respond to usual care, semaglutide reduced symptoms.

    Peptide
    Semaglutide
    Outcome
    DecreaseDysmenorrhea symptoms
    Study

    n = 1

    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the semaglutide therapy was able to minimize the patient's symptoms to where she was able to continue activities of daily living
    1 context sentence
    Summary · context
    We present a case of a patient with severe refractory dysmenorrhea who was able to minimize symptoms with the use of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist.
  2. 02HumanCase report or seriesEfficacy outcome

    In one patient with severe refractory dysmenorrhea, semaglutide therapy was accompanied by less NSAID use.

    In plain wordsIn one woman with severe period pain, NSAID use fell while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseNSAID use
    Study

    n = 1

    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    minimize the use of NSAID therapy.
    1 context sentence
    Summary · context
    We present a case of a patient with severe refractory dysmenorrhea who was able to minimize symptoms with the use of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist.
  3. 03HumanCase report or seriesEfficacy outcome

    In one patient with refractory dysmenorrhea, body weight did not change on semaglutide.

    In plain wordsIn one woman with severe period pain, weight did not change while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the patient experienced no changes in weight and only transient loss of appetite while on semaglutide.
    1 context sentence
    Summary · context
    We present a case of a patient with severe refractory dysmenorrhea who was able to minimize symptoms with the use of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist.
  4. 04HumanCase report or seriesSafety outcome

    In one patient with refractory dysmenorrhea, semaglutide was accompanied by transient loss of appetite.

    In plain wordsIn one woman with severe period pain, semaglutide came with a short period of lost appetite.

    Peptide
    Semaglutide
    Outcome
    Not applicableLoss of appetite
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    only transient loss of appetite while on semaglutide.
    1 context sentence
    Summary · context
    We present a case of a patient with severe refractory dysmenorrhea who was able to minimize symptoms with the use of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.